Clinical trial
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
- Lead sponsor
- Institut de Recherches Internationales Servier
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- December 16, 2024
- Completion date
- September 13, 2027
- Enrollment
- 55 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced, unresectable or metastatic cholangiocarcinoma with an idh1 mutation